Opportunity
SAM #FDA-RFQ-13611
FDA CDER seeks Brightfield Group online data subscription and analytic services for cannabis and CBD research
Buyer
FDA Office of the Associate General Counsel for Administrative Law
Posted
August 12, 2026
Respond By
August 24, 2026
Identifier
FDA-RFQ-13611
NAICS
513210, 541910, 541690
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), is seeking a comprehensive online data subscription and analytic services from Brightfield Group to support research, policy, and regulatory activities related to cannabis, cannabidiol (CBD), and emerging products. - Government Buyer: - Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) - OEM/Vendor: - Brightfield Group - Products/Services Requested: - Brightfield Group online data subscription and analytic services (1 subscription) - User support and training for unlimited FDA staff - Annual CBD and emerging non-intoxicating cannabis product market data - Biannual CBD and emerging non-intoxicating cannabis product consumer data - Daily social listening monitoring of TikTok, Instagram, and Reddit with AI modeling - Quarterly General Population Survey and social conversation tracking - Biannual US Cannabis Consumer Survey and social listening monitoring - Annual Womens Health Study Survey and social listening tracking (one wave, 5000 US women) - Ad hoc work on emerging concerns and quarterly reports - Unique/Notable Requirements: - Unlimited access for FDA staff via password-protected website - Live group training sessions and technical support - Multiple survey types and social listening analytics with dashboard access - Ad hoc research and quarterly reporting tailored to FDA needs - Period of Performance: - 12-month contract duration with no option years - No specific part numbers provided; all services are delivered as a single subscription package.
Description
The Food and Drug Administration (FDA) requires Brightfield Group online data subscription and analytic services to help address knowledge gaps on cannabis, cannabidiol (CBD), and emerging products and help inform work on policy and regulation, education and outreach, and compliance activities.